The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Open accessAbstract
Purpose: Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer. Patients and Methods: Patients with advanced pancreatic cancer were stratified according to center, performance status, and type of disease (locally advanced v metastatic) and randomly assigned to either GemOx (gemcitabine 1 g/m 2 as a 100-minute infusion on day 1 and oxaliplatin 100 mg/m 2 as a 2-hour infusion on day 2 every 2 weeks) or Gem (gemcitabine 1 g/m 2 as a weekly 30-minute infusion). Results: Three hundred twenty-six patients were enrolled; 313 were eligible, and 157 and 156 were allocated to the GemOx and Gem arms, respectively. GemOx was superior to Gem in terms of response rate (26.8% v 17.3%, respectively; P = .04), progression-free survival (5.8 v 3.7 months, respectively; P = .04), and clinical benefit (38.2% v 26.9%, respectively; P = .03). Median overall survival (OS) for GemOx and Gem was 9.0 and 7.1 months, respectively (P = .13). GemOx was well tolerated overall, although a higher incidence of National Cancer Institute Common Toxicity Criteria grade 3 and 4 toxicity per patient was observed for platelets (14.0% for GemOx v 3.2% for Gem), vomiting (8.9% for GemOx v 3.2% for Gem), and neurosensory symptoms (19.1% for GemOx v 0% for Gem). Conclusion: These results confirm the efficacy and safety of GemOx, but this study failed to demonstrate a statistically significant advantage in terms of OS compared with Gem. Because GemOx is the first combined treatment to be superior to Gem alone in terms of clinical benefit, this promising regimen deserves further development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citationTrends in the Aggressiveness of Cancer Care Near the End of Life
Earle, C. C., Neville, B. A., Landrum, M. B., Ayanian, J. Z., Block, S. D., & Weeks, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.136 · Cited by 987
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Urdaneta, A. B. (1972) · PubMed · Cited by 632
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600446 · Cited by 557
Tempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., & Abbruzzese, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.140 · Cited by 519
Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M., & Abbruzzese, J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.040 · Cited by 479
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.098 · Cited by 396
Eosewicz, S., & Wiedenmann, B. (1997) · The Lancet · doi:10.1016/s0140-6736(96)05523-7 · Cited by 229
Louvet, C., André, T., Lledo, G., Hammel, P., Bleiberg, H., Bouleuc, C., Gamelin, E., Flesch, M., Cvitkovic, E., & de Gramont, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1512 · Cited by 223
Self-citationCuly, C. R., Clemett, D., & Wiseman, L. R. (2000) · Drugs · doi:10.2165/00003495-200060040-00005 · Cited by 217
Faivre, S. J., Raymond, É., WOYNAROWSKI, J. M., & Cvitkovic, E. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050955 · Cited by 148
Ducreux, M. P., Mitry, E., Ould-Kaci, M., Boige, V., Seitz, J. F., Bugat, R., Breau, J. L., Bouché, O., Etienne, P.-L., Tigaud, J., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh098 · Cited by 119
Self-citationRichards, D., Kindler, H. L., Oettle, H., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., John, W. J., Arning, M., & Hoff, D. D. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4007 · Cited by 74
O'Reilly, E. M., Abou-Alfa, G. K., Letourneau, R., Harker, W. G., Modiano, M., Hurwitz, H. I., Tchekmedyian, N. S., Ackerman, J., Jager, R. L. D., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4006 · Cited by 73
Kindler, H. L., Friberg, G. R., Stadler, W. M., Singh, D. A., Locker, G. Y., Nattam, S. R., Kozloff, M. F., Kasza, K., & Vokes, E. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4009 · Cited by 51
The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas
Hoff, P. M. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00406-8 · Cited by 14
Laparoscopic radiofrequency ablation and systemic chemotherapy for colorectal liver metastases
McCain, D. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3776 · Cited by 13
Neninger, E., Gonzalez, G., Crombet, T., Fleites, G., Leonard, I., Gonzalez, M., Badia, T., & Lage, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2610 · Cited by 6
Cited by
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Metadata
- Authors
- Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., Faroux, R., Lepere, C., & de Gramont, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-05-20
- Volume
- 23
- Issue
- 15
- Pages
- 3509-3516
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097642908
- Cited by
- 950
- References
- 22
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.